PODXL and glioblastoma: Subsequent studies have confirmed podocalyxin as a prognostic indicator of poor outcome in a variety of malignancies, including ovarian, prostate, renal, pancreatic, thyroid, glioblastoma, astrocytoma, colorectal and bladder cancers [10-18].